This page was printed from the Northern & Eastern Devon Formulary and Referral site at
Please ensure you are using the current version of this document
Please see section 14.2 Immunoglobulins for immunoglobulin therapies
Please refer to Cholera (The Green Book; Chapter 14) for further information, including dosing and treatment regimens
Please see International travel for advice on immunisation for travel abroad
For the latest updates and advice on COVID-19, please visit the NHS website
For a summary of Formulary updates specific to the COVID-19 pandemic, please click here
For Clinical Referral Guideline (CRG) updates specific to the COVID-19 pandemic, please click here
Please refer to COVID-19 (The Green Book; Chapter 14a) for further information, including dosing and treatment regimens
The use of these vaccines should be in accordance with national recommendations. Documents relating to the new coronavirus (COVID-19) vaccination programme, including; protocols and patient group directives (PGDs), can be found here.
MHRA information and guidance for industry, healthcare professional, and patients on coronavirus (COVID-19) can be found here
Information and guidance from across SPS on pharmaceutical aspects of COVID-19 vaccines’ use including cautions and contraindications, interactions, and safety in pregnancy and breastfeeding, see here.
To check for an interaction between a COVID-19 vaccine and individual drugs, see the following site: University of Liverpool COVID-19 Drug Interactions
Healthcare professionals are asked to report any suspected side effects to COVID-19 vaccines. Report using the dedicated Coronavirus Yellow Card reporting site or the Yellow Card app
NICE has issued the COVID-19 rapid guideline NG200: vaccine-induced immune thrombocytopenia and thrombosis (VITT). The guideline covers VITT, a syndrome which has been reported in rare cases after COVID-19 vaccination.
Diphtheria and tetanus vaccines are only given as part of combined products
Please refer to Diphtheria (The Green Book; Chapter 15) for further information, including dosing and treatment regimens
Please refer to Tetanus (The Green Book; Chapter 30) for further information, including dosing and treatment regimens
Please refer to Polio (The Green Book; Chapter 26) for further information, including dosing and treatment regimens
Please see International travel for advice on immunisation for travel abroad
Hib vaccines are available as part of combined products DTaP/IPV/Hib (above) or Hib/MenC
Please refer to Haemophilus influenzae type b (Hib) (The Green Book; Chapter 16) for further information, including dosing and treatment regimens
The Joint Committee on Vaccination and Immunisation (JCVI) has been notified of the discontinuation of Menitorix (Hib/MenC). This necessitates a change to the routine schedule as this vaccine is currently given at 12 months. Please refer to the Joint Committee on Vaccination and Immunisation (JCVI) interim statement on the immunisation schedule for children (05 August 2022).
Please see International travel for advice on immunisation for travel abroad
Hepatitis A vaccines are available as either monovalent, or combined with hepatitis B
Please refer to Hepatitis A (The Green Book; Chapter 17) for further information, including dosing and treatment regimens
Please see International travel for advice on immunisation for travel abroad
Guidance for hepatitis A and B vaccination in drug users in primary care
For information on combination Hepatitis A and B vaccines in drugs users in primary care, please refer to Drug misuse and dependence: UK guidelines on clinical management (Department of Health and Social Care) (Also called 'The Orange Book')
Hepatitis B vaccines can be given as a single or combined product (Infanrix Hexa®, above)
Please refer to Hepatitis B (The Green Book; Chapter 18) for further information, including dosing and treatment regimens
Immunisation against hepatitis B is recommended for patients already on dialysis or renal transplantation programmes and for other patients with chronic renal failure as soon as it is anticipated that they may require these interventions.
People who will need dialysis or may have a kidney transplant in the future are all offered immunisation.
The commissioning and provision of Hepatitis B Vaccination for patients with Chronic Kidney Disease (CKD) is the responsibility of renal services in secondary care.
Nephrology outpatient activity remains the commissioning responsibility of ICBs.
The vaccines formulated for use in patients with chronic renal insufficiency should be used, see drug entries below.
Please refer to Chronic Kidney Disease CRG for information on detection and classification of CKD
Specific information regarding the safety of adults with chronic kidney disease and what you need to stop or start (NICE COVID-19 rapid guideline NG176) during the Coronavirus (COVID-19) pandemic can be found here.
Please see International travel for advice on immunisation for travel abroad
See Public Health England Cervical screening: professional guidance
Please refer to Human papillomavirus (HPV) (The Green Book; Chapter 18a) for further information, including dosing and treatment regimens
The national annual flu immunisation programme, can be found here (DHSC, PHE, and NHSE)
National flu immunisation programme plan (DHSC, PHE, and NHSE)
Please refer to Influenza (The Green Book; Chapter 19) for further information, including dosing and treatment regimens
Please see Upper respiratory tract infections for Influenza (flu) guidance
Annual guidance may change; check the GOV.UK website (seasonal influenza) for latest updates.
Please refer to Measles (The Green Book; Chapter 21) for further information, including dosing and treatment regimens
Please refer to Mumps (The Green Book; Chapter 23) for further information, including dosing and treatment regimens
Please refer to Rubella (The Green Book; Chapter 28) for further information, including dosing and treatment regimens
Pregnancy should be avoided for one month following MMR vaccination.
Please refer to Meningococcal (The Green Book; Chapter 22) for further information, including dosing and treatment regimens
A conjugate of Haemophilus type B and Meningococcal group C is available, see section on Haemophilus type B (above).
Please refer to Pneumococcal (The Green Book; Chapter 25) for further information, including dosing and treatment regimens
Please refer to Respiratory syncytial virus (The Green Book; Chapter 27a) for further information, including dosing and treatment regimens
Passive immunisation for RSV listed elsewhere in the formulary:
Please refer to Rotavirus (The Green Book; Chapter 27b) for further information, including dosing and treatment regimens
Please refer to Tuberculosis (The Green Book; Chapter 32) for further information, including dosing and treatment regimens
Please see International travel for advice on immunisation for travel abroad
Typhoid vaccines are available as either monovalent, or combined with hepatitis A (see above).
Please refer to Typhoid (The Green Book; Chapter 33) for further information, including dosing and treatment regimens.
Please see International travel for advice on immunisation for travel abroad
The Department of Health recommends varicella-zoster vaccine for seronegative healthcare workers who come into direct contact with patients. Those with a history of chickenpox or shingles can be considered immune, but healthcare workers with a negative or uncertain history should be tested.
After vaccination, contact with the following should be avoided if a vaccine-related cutaneous rash develops within 4-6 weeks of the first or second dose:
Healthcare workers who develop a generalised papular or vesicular rash on vaccination should avoid contact with patients until the lesions have crusted.
Please refer to Varicella (The Green Book; Chapter 34) for further information, including dosing and treatment regimens
Please refer to Shingles (herpes zoster) (The Green Book; Chapter 28a) for further information, including dosing and treatment regimens
The eligible age for immunocompetent individuals will change from 70 to 60 years of age for the routine cohort, in a phased implementation over a 10 year period.
The routine offer will move from 70 to 60 years of age in 2 stages over a 10 year period as follows:
During stage 1 (1 September 2023 to 31 August 2028)
Shingrix will be offered to those turning 70 and 65 years on or after 1 September 2023.
Zostavax will be offered to persons aged between 70 to 79 that were eligible for the vaccination programme before 1 September 2023. Once all stocks of Zostavax are exhausted, these individuals can be offered Shingrix if they have not previously been given a shingles vaccine.
During stage 2 (1 September 2028 to 31 August 2033)
Shingrix will be offered to those turning 65 and 60 years of age.
From 1 September 2033 and thereafter, Shingrix will be offered routinely at age 60 years.
Those who have been previously eligible (in stages 1 and 2) will remain eligible until their 80th birthday.
For more information on the shingles vaccination programme, see here.
The following vaccines cannot be provided as an NHS service when required for travel immunisation
Please refer to Japanese encephalitis (The Green Book; Chapter 20) for further information, including dosing and treatment regimens
Please see International travel for advice on immunisation for travel abroad
Please refer to Rabies (The Green Book; Chapter 27) for further information, including dosing and treatment regimens
Please see International travel for advice on immunisation for travel abroad
Please refer to Tick-borne encephalitis (The Green Book; Chapter 31) for further information, including dosing and treatment regimens
Please see International travel for advice on immunisation for travel abroad
Please refer to Yellow fever (The Green Book; Chapter 35) for further information, including dosing and treatment regimens
Please see International travel for advice on immunisation for travel abroad
Home > Formulary > Chapters > 14. Immunological products and vaccines > 14.1 Vaccines and antisera
